---
title: "AstraZeneca (AZN) Wins FDA Approval for IMFINZI Bladder Cancer Regimen"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305514953.md"
description: "The FDA has approved AstraZeneca's IMFINZI combined with enfortumab vedotin-ejfv as a perioperative treatment for adults with muscle-invasive bladder cancer who cannot receive cisplatin. In the Phase III VOLGA trial, this regimen reduced the risk of disease recurrence or death by 49% and the risk of death by 42% compared to the comparator. This approval expands treatment options for a significant patient population, though it carries a higher rate of severe adverse events."
datetime: "2026-11-13T23:39:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305514953.md)
  - [en](https://longbridge.com/en/news/305514953.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305514953.md)
generator: "portal-rs"
---

# AstraZeneca (AZN) Wins FDA Approval for IMFINZI Bladder Cancer Regimen

The FDA approved AstraZeneca’s perioperative IMFINZI plus neoadjuvant enfortumab vedotin-ejfv regimen for adults with muscle-invasive bladder cancer who are ineligible for or have refused cisplatin. In VOLGA, it reduced EFS risk by 49% and death risk by 42% versus the comparator.

**Material Details**

| # | Detail                                               | AI Analyst View                                                                                                       |
| - | ---------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------- |
| 1 | FDA approved regimen for cisplatin-ineligible MIBC   | Adds a US-approved treatment option for a patient group that may represent up to half of MIBC patients.               |
| 2 | EFS risk reduced 49% vs. comparator                  | The Phase III result supports the regimen’s clinical case; estimated median EFS was not reached versus 12.1 months.   |
| 3 | Death risk reduced 42% vs. comparator                | Overall-survival results strengthen the evidence for the regimen; median OS was not reached in either arm.            |
| 4 | Grade 3/4 adverse events: 64% vs. 44%                | Higher severe adverse-event incidence than the comparator is a relevant trade-off for uptake and treatment decisions. |
| 5 | EU, Japan and other applications remain under review | Additional decisions could broaden the commercial opportunity, but timing and outcomes were not specified.            |

**Context by AI Analyst**

This is a third bladder cancer indication for IMFINZI in two years, extending the drug’s role into cisplatin-ineligible MIBC. Further regulatory decisions in the EU, Japan and other countries would be the next catalyst for broader adoption.

Based on the original press release from AstraZeneca distributed by BusinessWire.

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Summary is based on content distributed by BusinessWire. Please verify any important information with the original source. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)

## Related News & Research

- [AstraZeneca's sonesitatug vedotin gets FDA priority review for advanced gastric cancers](https://longbridge.com/en/news/306076537.md)
- [AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy](https://longbridge.com/en/news/305633730.md)
- [AZ beefs up myasthenia gravis pedigree with US, EU Klygefa nods](https://longbridge.com/en/news/305697522.md)
- [AstraZeneca secures FDA approval for Imfinzi combo in MIBC](https://longbridge.com/en/news/305649865.md)
- [AstraZeneca fends off lawsuit over alleged Soliris drug monopoly](https://longbridge.com/en/news/305701830.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**